BRAF and melanoma: Our work highlights LINC01198 as critical modulator for establishing resistance against vemurafenib in melanoma harboring BRAF mutation, which also provide a series of therapeutic targets together with vemurafenib for combination therapy of melanoma, especially in the fields of personalized medicine and precision therapy.